Glial Fibrillary Acidic Protein in Multiple System Atrophy (P10-7.003)

Wolfgang Singer; Ann Schmeichel; Pinaki Misra; Shannen Griffiths; Jennifer Anderson; David Sletten; Tonette Gehrking; Jade Gehrking; Prashanthi Vemuri; Phillip Low

doi:10.1212/wnl.0000000000217890

June 9, 2026Neurology

Glial Fibrillary Acidic Protein in Multiple System Atrophy (P10-7.003)

View Full Paper

Ask AI

Bookmark

Share

Key Points

This study aims to evaluate glial fibrillary acidic protein in cerebrospinal fluid as a diagnostic and progression marker for multiple system atrophy.
Conducted a prospective, longitudinal study of early synucleinopathies.
Participants were enrolled to evaluate cerebrospinal fluid.
Findings indicate GFAP levels may serve as a useful marker for diagnosing MSA.
GFAP was associated with the progression of MSA symptoms.

Implication

Assesses glial fibrillary acidic protein in cerebrospinal fluid as a marker for multiple system atrophy, indicating its diagnostic potential.

Abstract

To assess glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF) as diagnostic and/or progression marker for multiple system atrophy (MSA) among participants enrolled in a prospective, longitudinal study of early synucleinopathies.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Singer et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf3d6faef96ed7f0563a4 https://doi.org/10.1212/wnl.0000000000217890

View Full Paper

Ask AI

Bookmark

Share

Glial Fibrillary Acidic Protein in Multiple System Atrophy (P10-7.003)

Key Points

Implication

Abstract

Discussion

Cite This Study

Glial Fibrillary Acidic Protein in Multiple System Atrophy (P10-7.003)

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading